chrisvoncsefalvay/vaers-outcomes huggingface dataset:
got two different vaccines/ invalid dose (First dose from Moderna and second dose from Pfizer); felt tired after first dose; no energy after first dose; This spontaneous case was reported by a pharmacist and describes the occurrence of ASTHENIA (no energy after first dose), INCORRECT PRODUCT FORMULATION ADMINISTERED (got two different vaccines/ invalid dose (First dose from Moderna and second dose from Pfizer)) and FATIGUE (felt tired after first dose) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Feb-2021, the patient experienced ASTHENIA (no energy after first dose) and FATIGUE (felt tired after first dose). On an unknown date, the patient experienced INCORRECT PRODUCT FORMULATION ADMINISTERED (got two different vaccines/ invalid dose (First dose from Moderna and second dose from Pfizer)). At the time of the report, ASTHENIA (no energy after first dose) and FATIGUE (felt tired after first dose) outcome was unknown and INCORRECT PRODUCT FORMULATION ADMINISTERED (got two different vaccines/ invalid dose (First dose from Moderna and second dose from Pfizer)) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was reported.   No treatment information was provided.
No AE reported; Improperly stored and administered; This spontaneous report as received from a physician refers to a 4-year-old patient of unknown gender. Pertinent medical history, drug reactions, allergies and concomitant medications were not reported.  On 25-JUN-2021, the patient was vaccinated with an improperly stored dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (rHA) (M-M-R II) (lot number: T007230, expiration date: 27-FEB-2022; dose and route of administration not provided). The vaccine was stored in temperature below -50 degrees Celsius (-51 degrees Celsius) (also reported as below 2 degrees Celsius (-51 degrees Celsius)) for 14 hours. There was no previous temperature excursion. Digital data lodger was not involved.  No adverse event was reported.
Information has been received from a nurse referring to the patients of unknown age and gender. The patients' medical histories, concurrent conditions and concomitant therapies were not reported. The doses of PEDVAXHIB were improperly stored at 1.5 Celsius degree for 29 minutes on 15-AUG-2016. Prior excursions included 10.2 Celsius degree for 6 hours 35 minutes on 21-JUN-2016 and 1.4 Celsius degree for 53 minutes on 09-AUG-2016. On unknown dates in 2016 (reported as "after 15-AUG-2016"), the patients were vaccinated with improperly stored PEDVAXHIB (dose, lot #, expiration date and route not reported). No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
First Dose with Heplisav-B and Second Dose with Engerix; Initial Report Received on 21-Jun-2022  A pharmacist in the reported that a 69-year-old male patient (race and ethnicity unknown) received a dose of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization as the first dose and Engerix as the second dose.  Medical history at the time of vaccination was reported as unknown. The patient had no known allergies.  No concomitant medications at the time of vaccination were reported.  On 13-Apr-2022, the patient received the first dose of HEPLISAV-B (Lot # 4EA77, expiration date 13-Apr-2023, NDC # 43528-003-05; route and injection site unknown).  On 25-May-2022, 43 days after having been vaccinated with HEPLISAV-B, the patient received Engerix as the second dose instead (Lot # 9AX5P, expiration date 23-Nov-2023; NDC #, route, and injection site unknown). The patient did not report any adverse reactions.  No additional information was provided.  Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.
Sore on arm; Felt tired; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore on arm) and FATIGUE (Felt tired) in a 42-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 040B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Apr-2021, the patient experienced PAIN IN EXTREMITY (Sore on arm) and FATIGUE (Felt tired). At the time of the report, PAIN IN EXTREMITY (Sore on arm) and FATIGUE (Felt tired) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       No concomitant medication were provided.  No treatment medication were provided.   This case was linked to MOD-2021-293438, MOD-2021-294665 (Patient Link).
started menstruating 4 days early after the first dose of vaccine; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 13Sep2021 at 19:00 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included escitalopram (MANUFACTURER UNKNOWN) for an unknown indication from an unknown dates and unknown if ongoing. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously received ciprofloxacin (CIPRO) for an unknown indication on an unknown date and experienced drug allergy. On 16Sep2021 at 12:00, after the first dose of vaccine. the patient started menstruating 4 days early. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event started menstruating 4 days early was resolved with sequelae on an unknown date in 2021.  The lot number for BNT162b2 was not provided and will be requested during follow up.
I had a sore arm for about a day. I tested positive for COVID-19 on 12/17/2022 with a scratchy throat. I went to a clinic and got a prescription for Paxlovid. I tolerated the medication and was able to take all the prescription. I did experience the metallic taste.
stomach discomfort; This is a spontaneous report received from non-contactable reporter(s) (Consumer or other non HCP). Other Case identifier(s):.  A 52 year-old male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) at the age of 52 years as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ABDOMINAL DISCOMFORT (non-serious), outcome "unknown", described as "stomach discomfort".  Additional Information: Patient received COVID Vaccine and had a reaction mostly stomach discomfort.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Reported to co-worker that he developed scattered flat rash on the inner aspect of the forearm of vaccinated arm.  The following day, it progressed to generalized rash of the entire inner aspect of the forearm.  He was seen by a provider and was treated with Benadryl and steroids.
child got 50-75 pox, no fever;restless 2wk p/exposed to varicella;(had vaccine 6/10/96);
Case number PHEH2014US021401 is an initial spontaneous report received from a pharmacist on 23 Oct 2014. This report refers to a 30 years old female patient. Her medical history and concomitant medications were not reported. She was vaccinated FLUVIRIN (batch number: not reported) from multi-dose vial (MDV) intramuscularly on 22 Oct 2014. It was reported that she was breastfeeding at the time of FLUVIRIN vaccination. No adverse events were reported following the maladministration.
This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vaccinated with the Moderna Vaccine after the expiration of 25-Mar-2022) and PRODUCT STORAGE ERROR (received a vaccine past the 30 day storage on the refrigerator) in a 37-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L21A) for COVID-19 vaccination. The patient had no known drug allergies. Concurrent medical conditions included Asthma. Concomitant products included Melatonin; Acyclovir [Aciclovir]; Albuterol Sulfate for an unknown indication. On 20-Apr-2022 at 11:43 AM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Apr-2022 at 11:43 AM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (vaccinated with the Moderna Vaccine after the expiration of 25-Mar-2022). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (received a vaccine past the 30 day storage on the refrigerator). At the time of the report, EXPIRED PRODUCT ADMINISTERED (vaccinated with the Moderna Vaccine after the expiration of 25-Mar-2022) and PRODUCT STORAGE ERROR (received a vaccine past the 30 day storage on the refrigerator) outcome was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments. The vial was initially stored in refrigerator on 25-Feb-2022. The vial did not undergo temperature excursion. It was reported that the patient was vaccinated post 30 day use period (expiration date 25-Mar-2022). The patient did not experience any side effects. No treatment details were reported.
Information has been received from a health department nurse via a company representative concerning a 35-40 year old female patient, who came from a foreign country on 10-Jan-2003, who has a history of negative rubella titer, who on 11-Aug-2003 was vaccinated with a dose of MMR virus vaccine live. It was noted that the patient was vaccinated after giving birth on 11-Aug-2003. On 23-Aug-2003 a general rash developed. A rubella titer was done on 23-Aug-2003 and it was reported that her "ITM' and "ITT" were both negative. On 28-Aug-2003 the rash was gone. On 11-Sep-2003, the patient tested positive for rubella. Unspecified medical attention was sought. Additional information has been requested.
Patient experienced sweating after her second Moderna Covid-19 vaccine booster dose; Patient experienced fatigue after her second Moderna Covid-19 vaccine booster dose; Patient experienced chills after her second Moderna Covid-19 vaccine booster dose; Patient experienced sore arm after her second Moderna Covid-19 vaccine booster dose; This spontaneous case was reported by a patient and describes the occurrence of HYPERHIDROSIS (Patient experienced sweating after her second Moderna Covid-19 vaccine booster dose), FATIGUE (Patient experienced fatigue after her second Moderna Covid-19 vaccine booster dose), CHILLS (Patient experienced chills after her second Moderna Covid-19 vaccine booster dose) and PAIN IN EXTREMITY (Patient experienced sore arm after her second Moderna Covid-19 vaccine booster dose) in a 90-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HYPERHIDROSIS (Patient experienced sweating after her second Moderna Covid-19 vaccine booster dose), FATIGUE (Patient experienced fatigue after her second Moderna Covid-19 vaccine booster dose), CHILLS (Patient experienced chills after her second Moderna Covid-19 vaccine booster dose) and PAIN IN EXTREMITY (Patient experienced sore arm after her second Moderna Covid-19 vaccine booster dose). At the time of the report, HYPERHIDROSIS (Patient experienced sweating after her second Moderna Covid-19 vaccine booster dose), FATIGUE (Patient experienced fatigue after her second Moderna Covid-19 vaccine booster dose), CHILLS (Patient experienced chills after her second Moderna Covid-19 vaccine booster dose) and PAIN IN EXTREMITY (Patient experienced sore arm after her second Moderna Covid-19 vaccine booster dose) outcome was unknown.            No concomitant medications were reported. Patient received Second Moderna Covid-19 vaccine booster dose. No treatment information were reported.   Reporter did not allow further contact
SCH (subconjunctival hemorrhage) starting within 2 hrs - left eye (no previous history) - ongoing after 52 hours. 100.5 deg temp after 18 hours. Took 2 Tylenol. Normal temp after 30 hours.
1328- Patient came back into line at the outside booster clinic, and reported to employee that he was having a reaction to the vaccine. The patient had just recently left after his 15 minute wait time was over.  Nurses came with emergency bag to observe the patient. Patient reported that his face was swelling and numb, and that "I'm having tightness right here." while pointing to chest and throat.  Patient then reported that the swelling and numbness had happened with the past two vaccinations of Moderna.   The nurse asked if he had put down that he had a severe reaction to a vaccination. The patient stated, "Well of course not. Why would I?" 1350- Patient's BP was taken 150/70. EMS was called since the decision to give Epi was made. 1352- Epi given 0.3 mg in the right thigh. Patient was still saying that he was feeling tightness.  1401-EMS arrived on scene and took over as primary care giver for the patient .Patient was checked over. BP was stable, and patient was allowed to leave once EMS had completed their assessment and patient refused to go to hospital. Nurse was not aware of patient leaving until after he had left.
presents after a fall at home in the setting of lightheadedness and weakness, now with confirmed positive COVID-19 infection.  Fortunately, his vital signs have been stable and he is saturating well on room air.  However, weakness in the setting of the infection likely resulted in the fall.
soreness, fatigue, muscle aches, headache, diarrhea Narrative:  Other Relevant History:
Pt recv vax on 6/26/96; on 2/23/99 pt exp chicken pox
This spontaneous report as received from a physician refers to 2 patients of unknown ages. The patients were vaccinated with a dose of ZOSTAVAX (lot # not reported). No other co-suspects were reported. No concomitant medications were reported. The physician reported that on an unknown date, the patients experienced a local reaction at the injection site. The outcome of local reaction at the injection site was unknown. The relatedness for local reaction at the injection site was unknown for ZOSTAVAX. Additional information has been requested.
ON 6/4/2021 AROUND 1:00 AM, CLIENT STARTED WITH CHILLS AND FEVER.  SYMPTOMS PROGRESSED TO INCLUDE JOINT PAIN, SORE THROAT, COUGH, SNEEZING AND RUNNY NOSE.  ADVISED CLIENT TO GO TO PCP.  CLIENT STATES THAT SHE DOES NOT HAVE A PCP, DOES NOT HAVE INSURANCE AND DOES NOT HAVE A JOB.  AVISED TO GO TO NEAREST HOSPITAL ER TO BE CHECKED OUT.
Patient presented to the ED on 1/14 and was subsequently hospitalized on 1/15 for COPD exacerbation within 6 weeks of receiving covid vaccination.
Patient complained he was feeling dizzy about  5 minutes after vaccination. He was laid on the floor and legs elevated. Patient reported feeling better after several minutes. He also states he generally have this type of episode when it comes to needles. Patient left pharmacy with wife and expressed he was feeling fine.
This case was reported by a pharmacist via call center representative and described the occurrence of injection site erythema in a female patient who received SHINGRIX for prophylaxis. On 27th April 2018, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX the patient experienced injection site erythema, malaise and injection site swelling. On an unknown date, the outcome of the injection site erythema, malaise and injection site swelling were recovered/resolved. It was unknown if the reporter considered the injection site erythema, malaise and injection site swelling to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The healthcare professional stated that the patient experienced redness and swelling at the injection site the size of a softball that lasted 2 weeks, and also had general malaise that lasted about 2 weeks. The healthcare professional returned to pharmacy to receive 2nd dose of SHINGRIX to patient last night from the day of reporting. The health care professional did not yet administer her 2nd dose of SHINGRIX until he contacted GlaxoSmithkline to ask if patient would be able to receive her 2nd dose of SHINGRIX with these types of reactions to the 1st dose of SHINGRIX.  No further information was provided.
Welts in the torso and back; Fever; Chills; This spontaneous case was reported by a physician and describes the occurrence of URTICARIA (Welts in the torso and back), PYREXIA (Fever) and CHILLS (Chills) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 04L20A) for COVID-19 vaccination.    Co-suspect products included non-company products ESTRADIOL for an unknown indication, Blood pressure medication for an unknown indication and Vitamin supplement for an unknown indication.    No medical history was provided by the reporter.    On 01-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient started ESTRADIOL (unknown route) at an unspecified dose, Blood pressure medication (unknown route) at an unspecified dose and Vitamin supplement (unknown route) at an unspecified dose. On 02-Feb-2021, the patient experienced URTICARIA (Welts in the torso and back), PYREXIA (Fever) and CHILLS (Chills). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL ALLERGY [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency; PARACETAMOL (TYLENOL) at an unspecified dose and frequency; SERTRALINE HYDROCHLORIDE (SERTAC) at an unspecified dose and frequency and CORTISONE at an unspecified dose and frequency. At the time of the report, URTICARIA (Welts in the torso and back), PYREXIA (Fever) and CHILLS (Chills) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Varivax given in (L) upper arm on 8/27/07. 14.5cm x 9cm area of erythema with 4.5x2cm raised red, blistery area central to area of erythema.
Fever, Chills, Dizziness, Nausea, Low Blood Pressure, Fainting.   Passed out in bathroom on tile floor, hit my head and have a mild concussion,  Still a little nauseous and unsteady.
I got really sick where I could not sit up, severe nausea and vomiting, body aches and dizziness, malaise and abdominal pain, lasting for several days and then they stopped. At the time of the vaccine I was 15 weeks pregnant.  I went to urgent care and got a Covid test.  An ultrasound was also performed to monitor the baby.  My estimated date of delivery: 08-01-2021.
severe head aches; fatigue; body aches; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (severe head aches), FATIGUE (fatigue) and MYALGIA (body aches) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 21-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced HEADACHE (severe head aches), FATIGUE (fatigue) and MYALGIA (body aches). At the time of the report, HEADACHE (severe head aches), FATIGUE (fatigue) and MYALGIA (body aches) outcome was unknown.            Treatment and concomitant information is not reported.   This case was linked to MOD-2021-227778.
Temp excursion of 1.5 degrees for 34 minutes  Vial was opened with 30 days of excursion
pt called 6OCT92 refered to epidemiology c/o flu like sx since 2nd vax; pt seen by MD blood work done; MD found nothing wrong;
numbness left arm to elbow and left upper cheek, denies shortness of breath, denies itching, no rash noted, Initially refused Benadryl po instead requested to stay for observation for an additional 15minutes. Symptoms persisted, denies shortness of breath, ithcing, denies swelling of tongue, At 1500 Benadryl 25mg given po, patient stayed for observation for 15 minutes and was ready to leave at that time.
Vaccine recipient received COVID-19 Vaccine on 12/22/20 and 3 minutes after felt that they were going to pass out and developed dizziness and headache. Vaccine recipient was administered ketorolac 15 mg IV, acetaminophen 650 mg, IV fluids in the emergency department. Patient felt better and was subsequently discharged to home. During a follow-up phone call on 12/23, vaccine recipient reported that their symptoms have resolved and they were able to return to work.
Severe large joint pain, especially in the hips.  This is an ongoing issue.  Prednisone was taken for a few weeks, but after the course, the pain returned.
red, blotchy rash on knees, back of elbow, top of arm near injection site
Within 1 hr of receiving flu shot, pt states that she felt "fluttering in chest," rapid heart beat, and palpitations. Symptoms were resolved the following day. No treatment was given or sought.